Yi-Miao Zhang1, Qiu-Hua Gu1, Jing Huang1, Zhen Qu1, Xin Wang1, Li-Qiang Meng1, Fang Wang1, Gang Liu1, Zhao Cui2, Ming-Hui Zhao3. 1. Renal Division, Department of Medicine, Peking University First Hospital, Beijing, China; Institute of Nephrology, Peking University, Beijing, China; Key Laboratory of Renal Disease, Ministry of Health of China, Beijing, China; Key Laboratory of CKD Prevention and Treatment, Ministry of Education of China, Beijing, China; and. 2. Renal Division, Department of Medicine, Peking University First Hospital, Beijing, China; Institute of Nephrology, Peking University, Beijing, China; Key Laboratory of Renal Disease, Ministry of Health of China, Beijing, China; Key Laboratory of CKD Prevention and Treatment, Ministry of Education of China, Beijing, China; and cuizhao@bjmu.edu.cn. 3. Renal Division, Department of Medicine, Peking University First Hospital, Beijing, China; Institute of Nephrology, Peking University, Beijing, China; Key Laboratory of Renal Disease, Ministry of Health of China, Beijing, China; Key Laboratory of CKD Prevention and Treatment, Ministry of Education of China, Beijing, China; and Peking-Tsinghua Center for Life Sciences, Beijing, China.
Abstract
BACKGROUND AND OBJECTIVES: Glomerular IgM deposition is commonly shown in primary FSGS and sometimes accompanied by C3 deposition. Clinical presentation and treatment outcomes of these patients are not investigated in detail. DESIGN, SETTING, PARTICIPANTS, &MEASUREMENTS: One hundred six consecutive patients with biopsy-proven primary FSGS from 2004 to 2014 were enrolled retrospectively. Clinical features and treatment outcomes were compared between patients with and without IgM/C3 deposition. RESULTS: Fifty-eight (54.7%) patients presented with IgM glomerular deposition on sclerotic segments. C3 and C1q depositions were shown exclusively in patients with IgM deposition (34.5% versus 0.0%; P<0.001 and 8.6% versus 0.0%; P=0.04, respectively). Patients with IgM deposition were younger (median; range: 24.5; 18.8-39.0 versus 46.5; 26.0-64.0 years old; P=0.001), had higher level of serum IgM (142.5; 96.3-206.0 versus 107.0; 71.0-140.0 mg/dl; P=0.01), and had higher level of eGFR (median; range 97.7; 48.0-135.8 versus 62.1; 33.7-93.9 ml/min per 1.73 m(2); P=0.01) at the time of kidney biopsy. The percentage of sclerosis lesions was significantly higher in patients with C3 deposition (median; range: 21.7%; 15.3%-31.1% versus 9.2%; 6.6%-20.0%; P=0.002). Although patients received comparable immunosuppressive treatments during 58.9 (29.5-81.1) months of follow-up, a significantly higher prevalence of refractory cases (no response or steroid dependent) occurred in patients with combined IgM and C3 deposition compared with patients with IgM deposition alone or without IgM deposition (58.8% versus 22.2% versus 15.6%, respectively; P=0.004). Multivariate analysis identified combined IgM and C3 deposition (odds ratio, 11.32; 95% confidence interval, 2.26 to 56.65; P=0.003) as an independent risk factor for refractory patients; 19 of 98 patients developed renal dysfunction when their serum creatinine levels increased >30% from baseline and reached >1.5 mg/dl. Combined IgM and C3 deposition (hazard ratio, 5.67; 95% confidence interval, 1.34 to 23.84; P=0.02) was identified as an independent risk factor for renal dysfunction. CONCLUSIONS: Patients with primary FSGS and IgM and C3 deposition showed unfavorable therapeutic responses and worse renal outcomes, which indicate that IgM and C3 deposition might involve disease progression via complement activation.
BACKGROUND AND OBJECTIVES: Glomerular IgM deposition is commonly shown in primary FSGS and sometimes accompanied by C3 deposition. Clinical presentation and treatment outcomes of these patients are not investigated in detail. DESIGN, SETTING, PARTICIPANTS, &MEASUREMENTS: One hundred six consecutive patients with biopsy-proven primary FSGS from 2004 to 2014 were enrolled retrospectively. Clinical features and treatment outcomes were compared between patients with and without IgM/C3 deposition. RESULTS: Fifty-eight (54.7%) patients presented with IgM glomerular deposition on sclerotic segments. C3 and C1q depositions were shown exclusively in patients with IgM deposition (34.5% versus 0.0%; P<0.001 and 8.6% versus 0.0%; P=0.04, respectively). Patients with IgM deposition were younger (median; range: 24.5; 18.8-39.0 versus 46.5; 26.0-64.0 years old; P=0.001), had higher level of serum IgM (142.5; 96.3-206.0 versus 107.0; 71.0-140.0 mg/dl; P=0.01), and had higher level of eGFR (median; range 97.7; 48.0-135.8 versus 62.1; 33.7-93.9 ml/min per 1.73 m(2); P=0.01) at the time of kidney biopsy. The percentage of sclerosis lesions was significantly higher in patients with C3 deposition (median; range: 21.7%; 15.3%-31.1% versus 9.2%; 6.6%-20.0%; P=0.002). Although patients received comparable immunosuppressive treatments during 58.9 (29.5-81.1) months of follow-up, a significantly higher prevalence of refractory cases (no response or steroid dependent) occurred in patients with combined IgM and C3 deposition compared with patients with IgM deposition alone or without IgM deposition (58.8% versus 22.2% versus 15.6%, respectively; P=0.004). Multivariate analysis identified combined IgM and C3 deposition (odds ratio, 11.32; 95% confidence interval, 2.26 to 56.65; P=0.003) as an independent risk factor for refractory patients; 19 of 98 patients developed renal dysfunction when their serum creatinine levels increased >30% from baseline and reached >1.5 mg/dl. Combined IgM and C3 deposition (hazard ratio, 5.67; 95% confidence interval, 1.34 to 23.84; P=0.02) was identified as an independent risk factor for renal dysfunction. CONCLUSIONS:Patients with primary FSGS and IgM and C3 deposition showed unfavorable therapeutic responses and worse renal outcomes, which indicate that IgM and C3 deposition might involve disease progression via complement activation.
Authors: Gianluca Caridi; Roberta Bertelli; Francesco Scolari; Simone Sanna-Cherchi; Marco Di Duca; Gian Marco Ghiggeri Journal: Kidney Int Date: 2003-07 Impact factor: 10.612
Authors: Yasuhito Hamaguchi; Junji Uchida; Derek W Cain; Guglielmo M Venturi; Jonathan C Poe; Karen M Haas; Thomas F Tedder Journal: J Immunol Date: 2005-04-01 Impact factor: 5.422
Authors: Gianluca Caridi; Roberta Bertelli; Alba Carrea; Marco Di Duca; Paolo Catarsi; Mary Artero; Michele Carraro; Cristina Zennaro; Giovanni Candiano; Luca Musante; Marco Seri; Fabrizio Ginevri; Francesco Perfumo; Gian Marco Ghiggeri Journal: J Am Soc Nephrol Date: 2001-12 Impact factor: 10.121
Authors: Piero Ruggenenti; Barbara Ruggiero; Paolo Cravedi; Marina Vivarelli; Laura Massella; Maddalena Marasà; Antonietta Chianca; Nadia Rubis; Bogdan Ene-Iordache; Michael Rudnicki; Rosa Maria Pollastro; Giovambattista Capasso; Antonio Pisani; Marco Pennesi; Francesco Emma; Giuseppe Remuzzi Journal: J Am Soc Nephrol Date: 2014-01-30 Impact factor: 10.121
Authors: Joshua M Thurman; Maria Wong; Brandon Renner; Ashley Frazer-Abel; Patricia C Giclas; Melanie S Joy; Diana Jalal; Milena K Radeva; Jennifer Gassman; Debbie S Gipson; Frederick Kaskel; Aaron Friedman; Howard Trachtman Journal: PLoS One Date: 2015-09-03 Impact factor: 3.240
Authors: Benjamin M Forster; Robert Nee; Dustin J Little; Peter J Greasley; James B Hughes; Sarah M Gordon; Stephen W Olson Journal: Kidney360 Date: 2020-12-01
Authors: Howard Trachtman; Jennifer Laskowski; Cameron Lee; Brandon Renner; Andrew Feemster; Samir Parikh; Sarah E Panzer; Weixiong Zhong; Paolo Cravedi; Chiara Cantarelli; Liudmila Kulik; Zhiying You; Simon Satchell; Brad Rovin; Fei Liu; Susan L Kalled; V Michael Holers; Diana Jalal; Joshua M Thurman Journal: Am J Physiol Renal Physiol Date: 2021-08-30